NICE will be flexible - up to a point
This article was originally published in Scrip
NICEis never far from controversy, and its interim decision to reject the use of four novel kidney drugs in the national health serviceis no exception. It shows that the institute is still prepared to base its recommendations firmly on cost-benefit assessments.
You may also be interested in...
Progress is being made towards the implementation of the EU’s new patent system, but the UK’s insistence on severing all ties with the European Court could spell the end for its participation.
The recruitment process for the new executive director of the European Medicines Agency seems to be running to schedule.
Russia’s new drug traceability system won’t now be implemented until July, but companies that are ready and able are being encouraged to put the system through its paces in order to flush out any glitches.